WO2013173480A1 - Détection de récurrence de cancer de la vessie - Google Patents

Détection de récurrence de cancer de la vessie Download PDF

Info

Publication number
WO2013173480A1
WO2013173480A1 PCT/US2013/041188 US2013041188W WO2013173480A1 WO 2013173480 A1 WO2013173480 A1 WO 2013173480A1 US 2013041188 W US2013041188 W US 2013041188W WO 2013173480 A1 WO2013173480 A1 WO 2013173480A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
assay
protein
dna
sample
Prior art date
Application number
PCT/US2013/041188
Other languages
English (en)
Inventor
Anthony P. Shuber
Cecilia Fernandez
Original Assignee
Predictive Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/472,334 external-priority patent/US20120244536A1/en
Application filed by Predictive Biosciences, Inc. filed Critical Predictive Biosciences, Inc.
Publication of WO2013173480A1 publication Critical patent/WO2013173480A1/fr
Priority to US14/542,048 priority Critical patent/US20150079033A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

La présente invention concerne de manière générale des procédés de dépistage de récurrence de cancer. Les procédés de l'invention impliquent l'établissement de niveaux seuils pour un marqueur protéique afin d'obtenir une sensibilité prédéterminée à un test, le niveau seuil indiquant l'absence de cancer. Le procédé implique également l'établissement d'un niveau seuil pour deux marqueurs acides nucléiques ou plus, les marqueurs acide nucléique augmentant la spécificité du test sans diminuer sa sensibilité, et le niveau seuil indiquant l'absence de cancer. Les procédés peuvent en outre impliquer l'application d'un test dans un échantillon afin de déterminer un niveau dudit marqueur protéique et un niveau desdits marqueurs acides nucléiques, et d'identifier l'échantillon comme étant positif pour une récurrence de cancer si le niveau du marqueur protéique et celui des marqueurs acides nucléiques sont supérieurs à leurs niveaux seuils respectifs. Dans certains aspects de l'invention, les marqueurs acides nucléiques comprennent FGFR3, la vimentine et NID2. Dans certains aspects, le marqueur protéique comprend MMP2 ou MMP9.
PCT/US2013/041188 2007-08-17 2013-05-15 Détection de récurrence de cancer de la vessie WO2013173480A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/542,048 US20150079033A1 (en) 2007-08-17 2014-11-14 Detection of bladder cancer and recurrent bladder cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/472,334 2012-05-15
US13/472,334 US20120244536A1 (en) 2007-08-17 2012-05-15 Detection of Bladder Cancer Recurrence

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/472,334 Continuation US20120244536A1 (en) 2007-08-17 2012-05-15 Detection of Bladder Cancer Recurrence

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/840,777 Continuation-In-Part US20090047694A1 (en) 2007-02-23 2007-08-17 Clinical Intervention Directed Diagnostic Methods

Publications (1)

Publication Number Publication Date
WO2013173480A1 true WO2013173480A1 (fr) 2013-11-21

Family

ID=49584258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/041188 WO2013173480A1 (fr) 2007-08-17 2013-05-15 Détection de récurrence de cancer de la vessie

Country Status (1)

Country Link
WO (1) WO2013173480A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064529A1 (en) * 2007-09-14 2012-03-15 Predictive Biosciences, Inc. Detection of nucleic acids and proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120064529A1 (en) * 2007-09-14 2012-03-15 Predictive Biosciences, Inc. Detection of nucleic acids and proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ, C ET AL.: "A Noninvasive Multi-Analyte Diagnostic Assay: Combining Protein And DNA Markers To Stratify Bladder Cancer Patients.", RESEARCH AND REPORTS IN UROLOGY., vol. 2012, no. 4, 3 March 2012 (2012-03-03), pages 17 - 26 *
FERNANDEZ, C ET AL.: "A Novel Approach To Using Matrix Metalloproteinases For Bladder Cancer.", THE JOURNAL OF UROLOGY., vol. 182, November 2009 (2009-11-01), pages 2188 - 2194 *
KARNES, R ET AL.: "A Noninvasive Multianalyte Urine-Based Diagnostic Assay For Urothelial Cancer Of The Bladder In The Evaluation Of Hematuria.", MAYO CLIN PROC., vol. 87, no. 9, September 2012 (2012-09-01), pages 835 - 842 *
RENARD, I ET AL.: "Identification And Validation Of The Methylated TWIST1 And NID2 Genes Through Real-Time Methylation-Specific Polymerase Chain Reaction Assays For The Noninvasive Detection Of Primary Bladder Cancer In Urine Samples.", EURPOEAN UROLOGY., vol. 58, 5 August 2009 (2009-08-05), pages 96 - 104 *
SHORE, ND ET AL.: "Noninvasive Multianalyte Diagnostic Assay For Monitoring Bladder Cancer Recurrence.", RESEARCH AND REPORTS IN UROLOGY., vol. 2012, no. 4, 17 October 2012 (2012-10-17), pages 49 - 56 *

Similar Documents

Publication Publication Date Title
US20120252020A1 (en) Screening Assay for Bladder Cancer
WO2014182598A1 (fr) Dosage diagnostique combinant de l'acide nucléique cellulaire et de l'acide nucléique exempt de cellules
AU2016223532B2 (en) Biomarker panel for the detection of cancer
ES2616800T3 (es) Obtención de perfil de expresión génica en tejidos tumorales biopsiados
US8841095B2 (en) Detection of nucleic acids and proteins
Zonta et al. Assessment of DNA integrity, applications for cancer research
WO2013173485A1 (fr) Détection de cancers de la vessie
JP6603232B2 (ja) 膀胱がんの監視、診断、およびスクリーニング方法
JP2019162102A (ja) 末梢血中で、がんによって変化したｒｎａを検出するシステムおよび方法
US20150079033A1 (en) Detection of bladder cancer and recurrent bladder cancer
CA2801305A1 (fr) Detection d'acides nucleiques et de proteines
Duployez et al. Minimal residual disease monitoring in t (8; 21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA
CN114945687A (zh) 对疑似具有肺瘤变的受试者中的甲基化dna、rna和蛋白质的表征
US8852893B2 (en) Detection of nucleic acids and proteins
Cardenosa-Rubio et al. Combining asymmetric PCR-based enzymatic amplification with silicon photonic microring resonators for the detection of lncRNAs from low input human RNA samples
Hirano et al. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR
WO2013173478A1 (fr) Test de dépistage du cancer de la vessie
KR101704533B1 (ko) 간암 바이오마커로서의 ＥＲＲγ 및 이의 용도
US20120244536A1 (en) Detection of Bladder Cancer Recurrence
EP3301186B1 (fr) Méthode, séquences, compositions et trousse pour la détection de mutations dans le promoteur du gène htert
WO2013173475A2 (fr) Amorces pour analyser des séquences méthylées et procédés pour les utiliser
WO2013173480A1 (fr) Détection de récurrence de cancer de la vessie
WO2013173476A1 (fr) Dépistage du cancer
Mejía-Aranguré et al. Development and Validation of a One-Step RT-qPCR Assay for Identifying Common Fusion Gene Transcripts Associated with the Prognosis of Mexican Children with B-Lineage Acute Lymphoblastic Leukemia
US20130122494A1 (en) Detection of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13791233

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 11/03/2015).

122 Ep: pct application non-entry in european phase

Ref document number: 13791233

Country of ref document: EP

Kind code of ref document: A1